losartan has been researched along with Vasculitis in 8 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Vasculitis: Inflammation of any one of the blood vessels, including the ARTERIES; VEINS; and rest of the vasculature system in the body.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Besides its antihypertensive effects, losartan can modulate inflammation in cardiovascular disease." | 7.85 | Losartan attenuates the coronary perivasculitis through its local and systemic anti-inflammatory properties in a murine model of Kawasaki disease. ( Aiba, Y; Hayashi, K; Kato, M; Koga, Y; Matsuda, S; Mochizuki, H; Nakamura, H; Niimura, F; Sekine, K; Suganuma, E; Takahashi, O; Ukawa, T, 2017) |
| " Besides its antihypertensive effects, losartan can modulate inflammation in cardiovascular disease." | 3.85 | Losartan attenuates the coronary perivasculitis through its local and systemic anti-inflammatory properties in a murine model of Kawasaki disease. ( Aiba, Y; Hayashi, K; Kato, M; Koga, Y; Matsuda, S; Mochizuki, H; Nakamura, H; Niimura, F; Sekine, K; Suganuma, E; Takahashi, O; Ukawa, T, 2017) |
| " Further research is necessary to determine which AT1RBs and which dosing regimens are optimal." | 2.41 | Emerging role of angiotensin II type 1 receptor blockers for the treatment of endothelial dysfunction and vascular inflammation. ( Mancini, GB, 2002) |
| "Co-treatment with losartan prevented all changes." | 1.31 | Unchanged cardiac angiotensin II levels accompany losartan-sensitive cardiac injury due to nitric oxide synthase inhibition. ( Boer, P; Braam, B; Gröne, H; Hohbach, J; Joles, JA; Koomans, HA; Verhagen, AM, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chao, Y | 1 |
| Zhu, L | 1 |
| Qu, X | 1 |
| Zhang, J | 2 |
| Kong, X | 1 |
| Gu, Y | 1 |
| Pu, J | 1 |
| Wu, W | 1 |
| Ye, P | 1 |
| Luo, J | 1 |
| Yang, H | 1 |
| Chen, S | 1 |
| Suganuma, E | 1 |
| Niimura, F | 1 |
| Matsuda, S | 1 |
| Ukawa, T | 1 |
| Nakamura, H | 1 |
| Sekine, K | 1 |
| Kato, M | 1 |
| Aiba, Y | 1 |
| Koga, Y | 1 |
| Hayashi, K | 1 |
| Takahashi, O | 1 |
| Mochizuki, H | 1 |
| Apostolakis, S | 1 |
| Vlata, Z | 1 |
| Vogiatzi, K | 1 |
| Krambovitis, E | 1 |
| Spandidos, DA | 1 |
| Mancini, GB | 1 |
| Petnehazy, T | 1 |
| Stokes, KY | 1 |
| Russell, JM | 1 |
| Granger, DN | 1 |
| Han, SH | 1 |
| Koh, KK | 1 |
| Quon, MJ | 1 |
| Lee, Y | 1 |
| Shin, EK | 1 |
| Chen, MF | 1 |
| Xie, XM | 1 |
| Yang, TL | 1 |
| Wang, YJ | 1 |
| Zhang, XH | 1 |
| Luo, BL | 1 |
| Li, YJ | 1 |
| Verhagen, AM | 1 |
| Hohbach, J | 1 |
| Joles, JA | 1 |
| Braam, B | 1 |
| Boer, P | 1 |
| Koomans, HA | 1 |
| Gröne, H | 1 |
1 review available for losartan and Vasculitis
| Article | Year |
|---|---|
Emerging role of angiotensin II type 1 receptor blockers for the treatment of endothelial dysfunction and vascular inflammation.
Topics: Acrylates; Aged; Antihypertensive Agents; Benzimidazoles; Biomarkers; Biphenyl Compounds; Coronary A | 2002 |
1 trial available for losartan and Vasculitis
| Article | Year |
|---|---|
The effects of simvastatin, losartan, and combined therapy on soluble CD40 ligand in hypercholesterolemic, hypertensive patients.
Topics: Antihypertensive Agents; Blood Pressure; C-Reactive Protein; CD40 Ligand; Cross-Over Studies; Drug T | 2007 |
6 other studies available for losartan and Vasculitis
| Article | Year |
|---|---|
Inhibition of angiotension II type 1 receptor reduced human endothelial inflammation induced by low shear stress.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cells, Cultured; Endothelium, Vascular; Human Umbi | 2017 |
Losartan attenuates the coronary perivasculitis through its local and systemic anti-inflammatory properties in a murine model of Kawasaki disease.
Topics: Animals; Anti-Arrhythmia Agents; Anti-Inflammatory Agents; Cell Wall; Chemokine CCL2; Disease Models | 2017 |
Angiotensin II up-regulates CX3CR1 expression in THP-1 monocytes: impact on vascular inflammation and atherogenesis.
Topics: Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Atherosclerosis; Cell Adhesi | 2010 |
Angiotensin II type-1 receptor antagonism attenuates the inflammatory and thrombogenic responses to hypercholesterolemia in venules.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Platelets; Cell Movement; Endothelium, Vascu | 2005 |
Role of asymmetric dimethylarginine in inflammatory reactions by angiotensin II.
Topics: Amidohydrolases; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Arginine; Cell Adhesion; C | 2007 |
Unchanged cardiac angiotensin II levels accompany losartan-sensitive cardiac injury due to nitric oxide synthase inhibition.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Blood Pressure; Cardiomegaly; Dose-Respon | 2000 |